Table 5.
HE3286-0401 Heteroscedasticitya Between HE3286 and Placebo Changes from Baseline Values in Laboratory Parameters.
| Group | Day | Parameter | HE3286 | HE3286 > Placebo | Placebo | Placebo > HE3286 | |
|---|---|---|---|---|---|---|---|
| W test P | F test P | W test P | F test P | ||||
| Cohort 1 | 84 | ΔInsulind | >0.1 | >0.1 | <0.0001 | 0.007 | |
| ΔC-peptide | >0.1 | >0.1 | <0.0001 | 0.0495 | |||
| ΔFasting glucose | >0.1 | >0.1 | 0.02 | >0.1 | |||
| ΔHOMA2 %B | >0.1 | >0.1 | <0.0001 | >0.1 | |||
| ΔHOMA2 IR | >0.1 | >0.1 | 0.002 | 0.049 | |||
| Δleptin | >0.1 | >0.1 | 0.005 | >0.1 | |||
| Cohort 1 MCP-1 > 40b |
84 | ΔHbA1c | >0.1 | >0.1 | 0.006 | >0.1 | |
| ΔFasting glucose | >0.1 | >0.1 | 0.02 | >0.1 | |||
| ΔHOMA2 %B | >0.1 | >0.1 | <0.0001 | >0.1 | |||
|
| |||||||
| Cohort 2 | 84 | ΔnHbA1c | >0.1 | >0.1 | 0.04 | >0.1 | |
| ΔInsulin | >0.1 | >0.1 | >0.1 | 0.004 | |||
| ΔFasting glucose | >0.1 | >0.1 | 0.03 | >0.1 | |||
| ΔHOMA2 %B | >0.1 | >0.1 | >0.1 | 0.006 | |||
| ΔMCP-1 | >0.1 | >0.1 | 0.005 | >0.1 | |||
| ΔTriglycerides | >0.1 | >0.1 | <0.0001 | 0.007 | |||
| 112 | ΔnHbA1c | >0.1 | >0.1 | 0.0007 | >0.1 | ||
| ΔInsulin | >0.1 | >0.1 | >0.1 | 0.008 | |||
| ΔFructosamine | >0.1 | >0.1 | 0.002 | >0.1 | |||
| ΔHOMA2 %B | >0.1 | >0.1 | <0.0001 | 0.01 | |||
|
| |||||||
| Cohort 2 BMI > 31c |
84 | ΔHOMA2 %B | >0.1 | >0.1 | 0.007 | >0.1 | |
| ΔMCP-1 | >0.1 | >0.1 | >0.1 | 0.009 | |||
| ΔTriglycerides | >0.1 | >0.1 | >0.1 | 0.001 | |||
| 112 | ΔInsulin | >0.1 | >0.1 | <0.0001 | 0.001 | ||
| ΔC-peptide | >0.1 | >0.1 | <0.0001 | >0.1 | |||
| ΔHOMA2 %B | >0.1 | >0.1 | <0.0001 | >0.1 | |||
| ΔHOMA2 IR | >0.1 | >0.1 | <0.0001 | >0.1 | |||
| >0.1 | >0.1 | >0.1 | >0.1 | ||||
aHeteroscedasticity describes differences in variances between groups. bParticipants with baseline monocyte chemoattractant protein greater than the lowest tertile (40 pmol/L, see results). cParticipants with baseline body mass index greater than the median (31 kg/m2, see results). dAbbreviations: Δ: change in; HOMA2 %B: homeostatic model assessment of pancreatic beta cell function; HOMA2 IR: homeostatic model assessment of insulin resistance; HbA1c: hemoglobin A1c; nHbA1c: HbA1c normalized to 84 day average hemoglobin mass; MCP-1: monocyte chemoattractant protein-1.